Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2025-12-27 @ 11:53 PM
Study NCT ID:
NCT04980534
Status:
COMPLETED
Last Update Posted:
2022-04-13
First Post:
2021-07-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C551853', 'term': 'Viusid'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'SUPPORTIVE_CARE', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 80}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-01-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-07', 'completionDateStruct': {'date': '2021-09-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-04-05', 'studyFirstSubmitDate': '2021-07-26', 'studyFirstSubmitQcDate': '2021-07-26', 'lastUpdatePostDateStruct': {'date': '2022-04-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-07-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-06-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean duration of hospitalization.', 'timeFrame': '21 days', 'description': 'Media of time in days to discharge in each group. Discharge is considered once the patient complete the following conditions:\n\n* Normal body temperature for 2 days (36.1 - 37.2 degrees Celsius will be considered as normal body temperature).\n* Normal appetite for 4 days.\n* Normal Complete Blood Count (CBC): Following values will be considered as normal values in CBC:\n\nRed blood cell count: Male: 4.35-5.65 million cells/mcL; Female: 3.92-5.13 million cells/mcL. Hemoglobin: Male: 13.2-16.6 grams/dL; Female: 11.6-15 grams/dL. Hematocrit: Male: 38.3-48.6 percent; Female: 35.5-44.9 percent. White blood cell count: 3,400 to 9,600 cells/mcL. Platelet count: Male: 135-317 billion/L; Female: 157-371 billion/L.\n\n* No requirement in oxygen support.\n* Decrease in or normal CRP: 0.8-1.0 mg/dL (or 8-10 mg/L) or lower will be considered as normal values.\n* Any decrease in IL-6 level lower than doubled normal value: between 0 and 43.5 pg/ml will be considered as normal values.'}], 'secondaryOutcomes': [{'measure': 'Mean levels of IL-6 concentration', 'timeFrame': '21 days', 'description': 'Mean of IL-6 concentration measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. IL-6 level lower than doubled normal value: between 0 and 43.5 pg/ml will be considered as normal values.\n\nLevels of IL-6 will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/).'}, {'measure': 'Peripheral blood c-reactive protein concentration', 'timeFrame': '21 days', 'description': 'Peripheral blood c-reactive protein concentration measured by blood biochemical analysis at day 0, 5, 10, 15 and 21.\n\n\\- 0.8-1.0 mg/dL (or 8-10 mg/L) or lower will be considered as normal values.\n\nLevels of CRP will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/).'}, {'measure': 'Mean levels of D-Dimer concentration', 'timeFrame': '21 days', 'description': 'Mean of D-dimer measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. D-Dimer level under 250 ng/mL, or under 0.4 μ/mL will be considered as normal value.\n\nLevels of D-Dimer will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/).'}, {'measure': 'Mean levels of Ferritin concentration', 'timeFrame': '21 days', 'description': 'Mean of D-dimer measured by blood biochemical analysis at day 0, 5, 10, 15 and 21. In adult Males between 12 to 300 ng/mL; in adult Females between 12 to 150 ng/mL will be considered as normal values.\n\nLevels of Ferritin will be determined centrally at OLYMP diagnostics lab (https://www.kdlolymp.kz/).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['covid-19', 'supportive care', 'Immuno-modulator', 'antiviral', 'symptoms relieve'], 'conditions': ['Covid19', 'COVID-19 Pneumonia', 'COVID-19 Respiratory Infection', 'Viral Infection', 'Respiratory Tract Infections', 'Infection, Coronavirus', 'SARS-CoV2 Infection']}, 'referencesModule': {'references': [{'pmid': '17311621', 'type': 'RESULT', 'citation': 'Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 2007 Mar;27(2):247-59. doi: 10.1111/j.1478-3231.2006.01411.x.'}, {'pmid': '20518086', 'type': 'RESULT', 'citation': 'Gomez EV, Perez YM, Sanchez HV, Forment GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M, Fabian LG. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol. 2010 Jun 7;16(21):2638-47. doi: 10.3748/wjg.v16.i21.2638.'}, {'pmid': '19691668', 'type': 'RESULT', 'citation': 'Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, Yasells Garcia A, Del Rosario Abreu Vazquez M. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2009 Nov 15;30(10):999-1009. doi: 10.1111/j.1365-2036.2009.04122.x. Epub 2009 Aug 18.'}], 'seeAlsoLinks': [{'url': 'https://www.researchgate.net/publication/340522164_Nueva_alternativa_para_el_tratamiento_para_Covid_19_en_Ecuador', 'label': 'Related Info'}, {'url': 'https://clinicaltrials.gov/ct2/show/NCT04407182', 'label': 'Related Info'}, {'url': 'https://www.hilarispublisher.com/open-access/effectiveness-of-viusid-and-asbrip-in-hospitalized-patients-infected-by-sarscov2-and-mildtomoderate-respiratory-illness-.pdf', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.', 'detailedDescription': 'This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.\n\nA total of 80 subjects will be randomized 2:1 in this study. 50 patients will be assigned to receive daily oral doses of 4,5 g of Viusid every 12 hours and 10 ml of Asbrip every 12 hours and standard care with antivirals or not. Other 30 patients will be assigned to receive only standard care.\n\nTreatment duration: 21 days\n\nObjective of the study: to increase the effectiveness of therapy for patients with Covid-19 using food supplements Viusid and Asbrip.\n\nResearch objectives:\n\n1. To assess the clinical symptoms of Covid-19 in patients on the background of combination therapy with the inclusion of food supplements Viusid + Asbrip.\n2. To investigate the dynamics of indicators of laboratory diagnostics against the background of complex therapy with the inclusion of food additives Viusid + Asbrip in the complex treatment of Covid -19.\n3. To study the dynamics of indicators of instrumental methods of treatment.\n4. To develop an algorithm for the management of patients with coronavirus infection in order to increase the effectiveness of therapy and rehabilitation of patients with this pathology.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "The eligibility criteria for inclusion in the study were as follows:\n\n* Male and female hospitalized patients who have signed an informed consent.\n* Aged between 18-85 years old.\n* RT-PCR confirmed COVID-19.\n* Fever (over 37.2 Celsius degrees).\n* CT scan percentage area of lung involvement with ground-glass opacities \\< 50 %.\n* Respiratory rate \\< 20-30 /min\n* SpO2 ≥ 95%.\n\nThe exclusion criteria were as follows:\n\n* Oxygen support (ventilation and non-invasive)\n* Uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings.\n* Any known intolerability to any of the study regimens' components.\n* Patient's family or official relations with a member of staff of the clinical site.\n* Patient's failure to assess his/her physical and/or emotional condition.\n* Patient's failure to comply with the study requirements.\n* Patient's refusal to participate in the study.\n* Pregnancy or breastfeeding."}, 'identificationModule': {'nctId': 'NCT04980534', 'briefTitle': 'Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip', 'organization': {'class': 'INDUSTRY', 'fullName': 'Catalysis SL'}, 'officialTitle': 'Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip', 'orgStudyIdInfo': {'id': 'COVID_KAZ_2021'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Viusid Plus Asbrip Adjuvant', 'description': '25 Patients who received standard therapy Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days AND Viusid (sachets with powder for dilution, oral administration) 1 sachet bid and Asbrip (liquid form, oral administration) 10 ml bid for the total duration of hospitalization. Time Frame: 21 days.', 'interventionNames': ['Dietary Supplement: Viusid and Asbrip', 'Drug: COVID-19 Standard Therapy']}, {'type': 'EXPERIMENTAL', 'label': 'Viusid Plus Asbrip Monotherapy', 'description': '25 Patients who did not receive standard antiviral therapy with the inclusion of food supplements Viusid (4.5 gr every 12 hours, oral administration) and Asbrip (10 mL every 12 hours, oral administration). Time Frame: 21 days.', 'interventionNames': ['Dietary Supplement: Viusid and Asbrip']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Control', 'description': '30 patients who received standard therapy (Remdesivir IV 200 mg for the first day and then 100 mg daily for the next 4 days), without the inclusion of food supplements Viusid and Asbrip.', 'interventionNames': ['Drug: COVID-19 Standard Therapy']}], 'interventions': [{'name': 'Viusid and Asbrip', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.', 'armGroupLabels': ['Viusid Plus Asbrip Adjuvant', 'Viusid Plus Asbrip Monotherapy']}, {'name': 'COVID-19 Standard Therapy', 'type': 'DRUG', 'description': 'Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.', 'armGroupLabels': ['Control', 'Viusid Plus Asbrip Adjuvant']}]}, 'contactsLocationsModule': {'locations': [{'zip': '010000', 'city': 'Astana', 'state': 'Astana', 'country': 'Kazakhstan', 'facility': 'City center for infectious diseases', 'geoPoint': {'lat': 51.1801, 'lon': 71.44598}}, {'zip': '020000', 'city': 'Astana', 'state': 'Astana', 'country': 'Kazakhstan', 'facility': 'City children hospital №1', 'geoPoint': {'lat': 51.1801, 'lon': 71.44598}}, {'zip': '010000', 'city': 'Astana', 'country': 'Kazakhstan', 'facility': 'JSC "Astana Medical University', 'geoPoint': {'lat': 51.1801, 'lon': 71.44598}}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Catalysis SL', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}